Germany-based therapeutic antibodies specialist MorphoSys has appointed Dr Malte Peters as its new chief development officer, succeeding Dr Arndt Schottelius from 1 March.
Dr Peters joins MorphoSys from Sandoz, where he served as global head of clinical development in its biopharmaceuticals business unit.
Prior to this, he was Novartis’ clinical head of oncology translational medicine and head of its Basel and East Hanover sites, and served as head of translational research and pharmacogenomics at Merck KGaA.
During this time he also held teaching appointments in internal medicines and biochemistry at the University of Mainz, in Germany.
Dr Gerald Möller, chairman of MorphoSys’ supervisory board, said: “Dr Peters is an ideal addition to the management board of MorphoSys at this stage of the company’s growth.
“Drawing on his deep operational and medical experience in oncology and immunology, he will focus his efforts on the development of our clinical and pre-clinical programmes, the most valuable assets driving out future growth.”